Please select the option that best describes you:
How do you manage the development of neuropathy in patients receiving bortezomib for multiple myeloma?
At what point is the neuropathy a contraindication to further bortezomib therapy?
Answer from: Medical Oncologist at Community Practice
Bortezomib and thalidomide cause the bulk of the neuropathy in myeloma patients worldwide, although thalidomide is rarely used in the U.S. because of more effective immune modulating drugs (IMiD's) available such as lenalidomide and pomalidomide. Pre-existing peripheral neuropathy is the biggest ri...
Sign in or Register to read more